Given the putative regulation of CLDN4 by AP-1 through AP-1-binding sites in its promoter, mRNA expressions of CLDN4 within molecular subsets of colorectal cancers were examined taking into consideration the presence of mutations in the upstream regulators KRAS and BRAF. This evidence concerns the gene FOS and colorectal cancer.